Uncategorized
Shire studies SHP640 for infectious conjunctivitis
The first U.S. patient has been enrolled in a phase 3 clinical trial for Shire’s SHP640, a combination broad-spectrum antiseptic and corticosteroid being evaluated for treating infectious keratitis in adults and children.International clinical trial sites are expected to open in the third quarter of 2017, according to an announcement from Shire.